Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED +0.99%79 Return-on-Tangible-Equity is 6.04% as of Mar. 2026, which is 4% below its 10-year median of 6.28. GuruFocus rates XTER:MED with a GF Score™ of 79/100 and a GF Value™ of €3.04 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 579 Healthcare Providers & Services companies, MediClin AG ranks better than 56.82% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MediClin AG's annualized net income for the quarter that ended in Mar. 2026 was €14.1 Mil. MediClin AG's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €233.9 Mil. Therefore, MediClin AG's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 6.04%.
The historical rank and industry rank for MediClin AG's Return-on-Tangible-Equity or its related term are showing as below:
XTER:MED'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -7.14 Med: 6.28 Max: 13.39
Current: 13.29
During the past 13 years, MediClin AG's highest Return-on-Tangible-Equity was 13.39%. The lowest was -7.14%. And the median was 6.28%.
XTER:MED's Return-on-Tangible-Equity is ranked better than 56.82% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.21
vs XTER:MED: 13.29
MediClin AG (XTER:MED) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MediClin AG Return-on-Tangible-Equity Related Terms
MediClin AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for MediClin AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:MED vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, MediClin AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MediClin AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.04% mean?
MediClin AG (XTER:MED) has a Return-on-Tangible-Equity of 6.04% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MediClin AG and its competitors. This is near median its historical median of 6.28. According to the industry distribution chart, MediClin AG ranks #250 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 43.2%.
Is MediClin AG's Return-on-Tangible-Equity too high?
MediClin AG's current Return-on-Tangible-Equity of 6.04% is near median its 10-year median of 6.28. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.21. MediClin AG's value of 6.04% is 40.8% below this industry median. Based on the distribution chart, MediClin AG ranks #250 out of 579 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MediClin AG has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #250 out of 579 companies for Return-on-Tangible-Equity. This puts MediClin AG in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.21. MediClin AG's value of 6.04% is 40.8% below this benchmark. While the company's 10-year median is 6.28 vs. the industry median of 10.21, MediClin AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.21, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediClin AG's current Return-on-Tangible-Equity of 6.04% is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MediClin AG and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediClin AG's current Return-on-Tangible-Equity is 6.04%, which is near median its own 10-year median of 6.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.04, compared to a current price of €4.08 — trading 34.2% above its estimated fair value. The current Return-on-Tangible-Equity is 6.04%, which is near median its 10-year median of 6.28 and 40.8% below the Healthcare Providers & Services industry median of 10.21. MediClin AG's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current Return-on-Tangible-Equity is 6.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €4.08 is trading 34.2% above its estimated GF Value™ of €3.04.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
Return-on-Tangible-Equity: 6.04% (near median its 10-year median of 6.28)
GF Value™: €3.04 vs. price of €4.08 (34.2% above fair value)
Industry Position: 40.8% below the Healthcare Providers & Services median (#250 of 579)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
79GF Score
Get the complete analysis for XTER:MED
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
